INTRODUCTION
While sites of lysine methylation are emerging for non-histone substrates, little is known about how the enzymes responsible for the addition and removal of methylation, KMTs (lysine methyltransferases) and KDMs (lysine demethylases), respectively, are impacting the associated targets or their downstream processes. Most studies are focused on how these enzymes are targeting nuclear proteins even though there are important roles outside the nucleus (1-3).
Therefore, studying the functions of KMTs and KDMs in the cytoplasmic compartment could reveal unexpected roles, which will likely identify relationships between these enzymes and signaling pathways (1) . Understanding the nuclear and cytoplasmic roles for these chromatin-modifying enzymes is important since they are commonly altered in cancer (4), impact numerous diseases (5) , and are emerging as important therapeutic targets.
In the present study, we describe a new and unexpected cytoplasmic role for the lysine demethylase KDM4A. KDM4A is a JmjC domain-containing enzyme that demethylates H3K9me3, H3K36me3 and H1.4K26me3 (6) . Previous studies have documented roles for KDM4A in modulating DNA replication, site-specific copy number regulation and gene expression (7) (8) (9) . These functions relate to the nuclear role of KDM4A; however, KDM4A is also localized to the cytoplasm, suggesting non-chromatin mediated functions. We report that KDM4A interacts with the translation initiation factors and is present in the initiating fractions of polysome profiles.
Consistent with these observations, KDM4A depletion altered the distribution of translation initiation factors in polysome profiles, reduced protein synthesis and enhanced the cell sensitivity and effect of mTOR inhibitors. Lastly, we demonstrate that chemical inhibition with JIB-04, a JmjC demethylase inhibitor, potently inhibits translation initiation, reduces overall translation and enhances mTOR inhibitor sensitivity. Taken together, the findings in this report reveal an unexpected direct interaction between KDM4A and components of the translation machinery and highlight KDM4A as well as other JmjC proteins as potentially new targets in combined cancer
RESULTS

KDM4A interacts with the translation initiation machinery
The lysine demethylase KDM4A is located in both the nucleus and cytoplasm ( Figure 1A ). For this reason, we performed mass spectrometry analysis on endogenously immunoprecipitated KDM4A from whole cell extracts to identify interacting proteins from both compartments. The interacting proteins from two independent immunoprecipitations were analyzed by Ingenuity Pathway Analysis (IPA), which revealed a significant enrichment for proteins involved in translation (p=1.74E-13 and 2.58E-14, respectively; Figure 1B ). We further confirmed these interactions with a separate KDM4A antibody by conducting co-immunoprecipitations ( Figure 1C ). Some of these associations were equal to, or more enriched than previously confirmed KDM4A interactors [e.g., compare eIF2α to MCM-7 or P53 (8, 10)]. We further strengthened these observations by isolating fractions from polysome profiles and western blotting for KDM4A and associated proteins as well as for positive controls for the collections. KDM4A was enriched in the translation initiating fractions: predominantly in the 40S fractions and to a lesser extent in the 60S fractions ( Figure 1D ; fractions 5-9). These data suggest that KDM4A could directly impact translation.
KDM4A impacts initiation factor distribution in 40/60/80S fractions
In order to understand the impact that KDM4A could have on the translation machinery, we siRNA depleted KDM4A and assessed whether the protein levels of translation-related factors were altered using multiplexed quantitative mass spectrometry-based proteomics (11) . We compared the proteome of unaltered and KDM4A depleted cells in biological duplicates. The protein levels of more than 8,200 individual proteins were quantified. We did not observe changes in levels for translation-related factors. In fact, proteins that are up-regulated (19 proteins greater that 1.7-fold) and down-regulated (four proteins decreased by 1.7-fold; Figure S1A ) did not have a significant enrichment in any particular category by IPA analysis (p<0.05). We observed only four proteins that were down regulated by more than 1.7-fold upon KDM4A depletion, including KDM4A ( Figure   S1A ). Consistent with our quantitative proteomics data, western blotting confirmed the absence of major differences in translation-related protein levels ( Figure S1B ).
Since KDM4A was present in the initiating fractions within the polysome profile, we assessed the impact KDM4A depletion had on initiation factor levels and distribution within the polysome fractions. KDM4A depletion resulted in the enrichment of initiation factors in certain fractions (i.e., 40S) and/or a redistribution of these factors such that there was an extension into larger fractions (i.e., 60/80S; Figures 2A and S1C). Figure 2A depicts the average change across two independent siRNA treated samples. The red bars highlight fractions with >20% change in protein levels for both independent siRNAs. We consistently observed an increase in eIF3A, FXR1, independent KDM4A siRNAs (see representative western blots and red bars in accompanying graphs); while, eIF3A, FXR1 and eIF2α presence is extended in larger fractions (fractions 11, 7 and 7-8, respectively). eIF5A is consistently enriched in fractions 5-6 upon KDM4A depletion, while PABP is stable across all fractions and serves as a normalization control.
We further investigated the impact that KDM4A had on initiation factor distribution by overexpressing enzymatically active and inactive KDM4A. We compared the distribution of translation factors in cells expressing GFP alone (GFP), catalytically active (GFP-WT) or inactive [GFP-H188A; (7)] KDM4A. For both GFP-WT and GFP-H188A, the distribution of initiation factors was altered. For example, eIF3A, FXR1 and eIF4A1 protein levels were consistently higher in fractions 6-11 (Figures 2B and S1D; red bars, >20% between independent experiments).
GFP-H188A appeared to have a more pronounced effect on certain initiation factors (i.e., eIF3A was higher in fractions 8-9 and FXR1 was increased in fractions 6-10). Interestingly, while GFP-WT and GFP-H188A had comparable expression ( Figure 2B exhibited much higher levels in fractions 5-9 ( Figure 2C ). These data are consistent with the catalytic activity being important for KDM4A distribution within the initiating fractions. Taken together, these data highlight the importance of balancing KDM4A protein levels so that proper distribution of translation initiation factors occur within polysome profiles, which supports a role for KDM4A in initiation complex assembly/disassembly ( Figure 2D ).
KDM4A depletion reduces protein synthesis
Since KDM4A interacts with translation factors and impacts their distribution, we hypothesized that KDM4A would have a role in protein synthesis. In order to test this possibility, we depleted KDM4A with two different shRNAs and assessed protein synthesis over two hours by measuring the incorporation of the methionine analog AHA (L-Azidohomoalanine) ( Figures 3A and S2A ).
KDM4A depletion significantly reduced the synthesis of nascent proteins ( Figure 3A ; 40%, p=1E-05).
We then assessed whether KDM4A depletion could enhance the inhibition of protein synthesis caused by drugs targeting translation initiation. mTOR is a well-recognized drug target involved in translation initiation (12, 13) . Therefore, we depleted KDM4A and assessed AHA incorporation with increasing doses of the mTOR inhibitor Rapamycin. Protein synthesis was further decreased in cells treated with all doses of Rapamycin combined with KDM4A shRNA depletion (Figures 3B and S2B). For example, 0.1ng/ml and 1ng/ml Rapamycin suppressed protein synthesis by ~20% and ~50%, respectively. However, 0.1ng/ml Rapamycin and 1ng/ml coupled to KDM4A depletion resulted in ~50% and 90% reduction in protein synthesis, respectively ( Figure 3B , the -actin ratio reported at the bottom represents the average of two independent experiments). These observations prompted us to assess the impact of KDM4A depletion on mTOR inhibitor sensitivity in cellular viability assays. As expected, KDM4A depletion coupled to Rapamycin treatment resulted in a statistically significant decrease in cell viability across all drug doses ( Figure 3C ). Consistent with these results, a polymorphism in KDM4A which results in reduced protein stability also confers sensitivity to mTOR inhibitors (14) .
Research. 
JmjC demethylase inhibition causes translation initiation defects
Previous studies report that KDM4 and KDM5A enzymes are chemical targets for JIB-04, an inhibitor of JmjC demethylases (15) . Interestingly, KDM5A is enriched on genes involved in mTOR, p70S6K and EIF2 signaling (16) . In fact, KDM5A depletion reduced the expression of ribosomal protein genes [e.g., RPL3, RPL7, RPL24; (16)]. These observations are in contrast with KDM4A, as we did not observe significant alterations in gene expression for genes involved in translation or mTOR signaling, suggesting that these enzymes could crosstalk to translation machinery in different ways ( Figure S3A ). Consistent with KDM5A regulating mTOR and translation factor genes (16), we observed an increased sensitivity to Rapamycin upon KDM5A depletion (Figures S3B-C) and a reduction in protein synthesis that was comparable to KDM4A depletion ( Figure S3D ). Since KDM4A was associated with the initiation complex, we also assessed whether KDM5A was present in the polysome fractions. Interestingly, KDM5A was present in the 40S/60S fractions of polysome profiles ( Figure S3E ). These data suggest that KDM5A could regulate protein synthesis at the level of gene expression and translation complexes. Furthermore, they suggest that multiple KDMs could be involved in regulating protein synthesis and the response to drugs such as Rapamycin. Therefore, we hypothesize that JIB-04 or related compounds could have a significant impact on sensitivity to mTOR inhibitors and protein synthesis by affecting both KDM4A and KDM5A or additional demethylases yet to be linked to protein synthesis.
In order to address this hypothesis, cells were co-treated with JIB-04 and Rapamycin or AZD8055 (two different mTOR inhibitors) before proliferation and viability was assessed ( Figure 4A 
DISCUSSION
In the present study, we assess the cytoplasmic role for KDM4A in protein synthesis. Altering the levels of KDM4A changed the distribution of translation initiation factors. This altered distribution could be due to the defective release of initiation factors since there was an accumulation of such factors in 40/60/80S fractions; however, KDM4A could also regulate additional events involved in translation or mRNA processing that could impact initiation and protein synthesis. Our data suggest that KDM4A directly affects initiation and protein synthesis because KDM4A interacts with the translation initiation machinery and is present in the initiating fractions of a polysome profile (i.e., 40S and 60S). Interestingly, there was more catalytically inactive KDM4A in the fractions where KDM4A is present. Therefore, catalytic activity appears to be important for properly regulating KDM4A distribution in these complexes, suggesting that components of the ribosome or ribosome-associated proteins are possible non-histone substrates of KDM4A.
However, our data also suggest that there could be a non-enzymatic function since overexpression of both catalytically active and inactive KDM4A impact initiation factors distribution. Therefore, future studies will be focused on understanding the enzymatic and 
non-enzymatic roles in modulating translation.
Our data demonstrate that reduced KDM4A levels are able to reduce overall protein synthesis without changing cell proliferation. However, the importance of this defect becomes enhanced with chemotherapeutics that target translation. The enhanced effect on translation inhibition correlates with stronger decrease in cell proliferation. These observations are reminiscent of KDM4A depletion resulting in enhanced chemotherapeutic sensitivity to DNA replication drugs, which is another process directly regulated by KDM4A (7) . Taken together, these data suggest that inhibition of KDM could potentiate the effect of mTOR inhibitors in the context of various cancer types. mTOR inhibition is a frontline therapy in the treatment of breast cancer and is being tested in ovarian cancer (17) (18) (19) . This study, albeit limited to a few models, suggests that breast cancer cells [ Figure S3B ; (20) ] and ovarian cancer cells ( Figure S3C ) might be sensitized by JIB-04 treatment in their response to mTOR inhibition. These data strongly support the combined use of these chemotherapeutics in other cancer cell types.
We also provide evidence that other KDMs such as KDM5A increase mTOR inhibitor sensitivity.
Interestingly, Tzatsos et al. demonstrated that KDM5A was enriched at target genes involved in protein synthesis and the mTOR pathway (16). Since we also observe an enrichment of KDM5A in polysome profile fractions this enzyme may impact protein synthesis and mTOR inhibitor sensitivity at multiple steps. Resolving whether one or both aspects are important for the impact of KDM5A on protein synthesis will be important for future studies. Lastly, these studies suggest that other enzymes (e.g., demethylases and methyltransferases) could be involved in pathways that crosstalk to translation or mTOR/PI3K signaling. Since many of these enzymes are altered in cancer (e.g., exhibit mutations, copy number variation or altered expression), they could act as additional biomarkers in treating cancer. Studies evaluating the KDM4A and KDM5A genetic and expression status in relation to treatment efficacy could allow for more refined patient Overall, the data presented in this study highlight the importance of understanding the impact enzymes have inside and outside the nucleus and of identifying the crosstalk between pathways for chemotherapeutics and chromatin regulators. The discovery that KDM4A or KDM5A depletion results in a decrease in protein synthesis suggests there is a benefit in targeting this group collectively. Therefore, the lack of currently available KDM-specific inhibitors could be balanced by the benefit of targeting groups of KDMs, especially in combined therapy. This strategy is currently being applied for HDACs (21) . The combined targeting of KDMs and translation could result in an effective therapy with reduced single agent toxicity; while, providing the advantage of reducing the emergence of resistant clones since both KDM4A and KDM5A have been linked to mechanisms that could promote resistance (8, 22) . These possibilities are important areas to explore in the future. Lastly, the current study highlights the fact that discovering unappreciated functions for chromatin modifiers can lead to the identification of associated signaling pathways and uncover optimal chemotherapeutic targets for the future.
EXPERIMENTAL PROCEDURES
Cell culture and drug treatments. For tissue culture procedures see (7) . Rapamycin (LC Laboratories) and AZD8055 (Selleckchem) were used at indicated concentrations. JIB-04 (Xcessbio) was used at a final concentration of 250nM or 500nM, as annotated. 20h prior to transfection. The complexes were incubated with the cells in OptiMEM for 4h before being replaced by fresh media. The transfected plasmids were: pMSCV-GFP (7), pMSCV-GFP-KDM4A (7), pMSCV-GFP-KDM4A-H188A (7), pSUPER (7) 
Western blot analysis. Western blot analyses were performed according to (7).
Cell Fractionation. Cytoplasmic, nuclear and chromatin fractions were prepared from RPE cells.
Cell pellets were washed twice in ice cold PBS and resuspended in ice cold Buffer A (10mM HEPES pH 7.9, 10mM KCl, 0.1M EDTA, 0.5M EGTA) and incubated on ice for 15 minutes. Lysed cells were centrifuged and the supernatant kept as cytoplasm. The nuclear pellet was resuspended in Buffer C (10mM HEPES pH 7.9, 400mM NaCl, 1mM EDTA, 5mM EGTA), dounced to resuspend and incubated at 4 degrees C for 30 minutes with rotation. Extracts were centrifuged and the supernatant kept as nuclear extract. Chromatin pellets were resuspended in N-Buffer (20mM Trish pH 7.5, 100mM KCl, 2mM MgCl2, 1mM CaCl2, 0.3M Sucrose, 0.1% Triton X-100, 3U per ml micrococcal nuclease. Samples were sonicated for 10 minutes at 70% amplitude in a Q700 cup horn and then incubated at room temperature for 15 minutes for MNase digestion. Reactions were stopped by addition of 5mM EGTA and centrifuged to clear.
Supernatant was kept as chromatin extract. For the western-blot analysis a comparable fraction of each compartment was loaded on a gel. The western-blot depicted in Figure 1A immunoprecipitations were performed with KDM4A-P006.
Co-immunoprecipitation. The co-immunoprecipitations experiments were performed as described in (23).
Mass spectrometry analysis on KDM4A immunoprecipitatons. Mass spectrometry analysis were performed as described in (8) . Microarrays analysis. For RNA expression analysis, RNA was extracted using MiRNeasy Mini kit (Qiagen). cDNA synthesis was performed with 2ug of total RNA using the Roche cDNA synthesis System (11 117 831 001, Roche). Hybridization of cDNA to Human Gene Expression 12x135K Arrays (Roche Nimblegen) was performed in triplicate according to manufacturer's protocol. Arrays were scanned using MS200 scanner (Roche Nimblegen) and extracted using Roche DEVA software. Raw expression array data was RMA-normalized and log2 transformed.
Differential expression t-tests were computed using the empirical Bayes shrinkage procedure implemented in the Limma R/Bioconductor package (25) . Two-fold up-or downregulated genes with a p-value <0.05 were considered differentially regulated. The accession number for the microarray analysis is GSE63812. 
